- First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - ...

TOKYO--(BUSINESS WIRE)--HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device ‘Alpha DaRT (Diffusing Alpha Radiation Therapy),’ developed by Alpha Tau ...

Dart Tech and LNS Solutions have joined forces to operate under the Dart brand, becoming the leading Managed Service Provider in the Tampa Bay area. The new Dart is redefining the region’s IT services ...

Alpha Tau Medical Ltd. announced significant advancements in their alpha-radiation cancer treatment, Alpha DaRT®, during the 2025 ASCO GI Symposium and R&D Update Day. Interim results from three ...

Alpha Tau reports promising Alpha DaRT trial results in pancreatic cancer and head and neck cancer, with significant survival benefits. High disease control rate (91% DCR) and positive interim safety ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...

Ashiq Mubarack, an analyst from Citi, has initiated a new Buy rating on Alpha Tau Medical Ltd (DRTS). Ashiq Mubarack has given his Buy rating due to a combination of factors surrounding the potential ...

JERUSALEM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, today announced ...